-
-
-
-
-
-
-
Analysis-Novo Nordisk CEO signals new appetite for risk in obesity deals
-
-
-
-
-
-
-
Novo Nordisk says Metsera bid won't raise antitrust issues
-
-
-
-
-
-
-
Pfizer said to mull suing Novo Nordisk over Metsera bid
-
-
-
-
-
-
-
Novo to buy Akero for up to $5.2 billion in new CEO's revival push
-
-
-
-
-
-
-
High Grade Gold Anomaly Extended at John Bull in Preparation for Drilling
-
-
-
-
-
-
-
Novo Nordisk earnings preview: BofA analysts weigh in ahead of Q4 results
-
-
-
-
-
-
-
BMO Capital: Five Key BioPharma Catalysts Through Year-End '24
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

